DBV DBV Technologies SA

DBV Technologies to Participate in Upcoming Investor Conferences

DBV Technologies to Participate in Upcoming Investor Conferences

Montrouge, France, November 9, 2020

DBV Technologies to Participate in Upcoming Investor Conferences

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participation in the following virtual investor conferences. At each conference, Daniel Tassé, Chief Executive Officer, will participate in a fireside chat.

Credit Suisse Healthcare Conference, November 9-12.

The fireside chat will take place on Wednesday, November 11, 2020 at 12:30PM ET.

Stifel Healthcare Conference, November 16.

The fireside chat will take place on Monday, November 16, 2020 at 8AM ET.  

Evercore HealthconX, December 1-3.

The fireside chat will take place on Tuesday, December 1, 2020 at 12:35PM ET.  

A live webcast of the fireside chats will be available on the Investors & Media section of the Company’s website:

A replay of the presentations will also be available on DBV’s website after the event.

About DBV Technologies

DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin™ is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV’s food allergies programs include ongoing clinical trials of Viaskin™ Peanut. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Relations Contact

Anne Pollak

+ 1 (857) 529-2363

Media Contact

Angela Marcucci

+ 1 (646) 842-2393

Attachment

EN
09/11/2020

Underlying

DBVDBV Technologies SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DBV Technologies SA

 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies Announces Sale of approximately $30 million of ADSs T...

DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq Châtillon, France, October 6, 2025 DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company, today announced that, pursuant to the Company’s At-The-Market program established on September 5, 2025 (the “ATM Program”), it has agreed to issue and sell new ordinary shares ...

14h / 45m 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies annonce un placement d’ADS pour un montant d’environ ...

DBV Technologies annonce un placement d’ADS pour un montant d’environ 30 millions de Dollars US dans le cadre de son programme At-The-Market (ATM) sur le Nasdaq Châtillon, France, 6 octobre 2025 DBV Technologies annonce un placement d’ADS pour un montant d’environ 30 millions de Dollars US dans le cadre de son programme At-The-Market (ATM) sur le Nasdaq DBV Technologies (la « Société » ou « DBV ») (Euronext : DBV - ISIN : FR0010417345 - Nasdaq Capital Market : DBVT), société biopharmaceutique en phase clinique, annonce ce jour, dans le cadre de son programme de financement dit « At-The-Ma...

14h / 45m 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies Announces Resignation of Board Member

DBV Technologies Announces Resignation of Board Member Châtillon, France, September 18, 2025 DBV Technologies Announces Resignation of Board Member DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the “Company” or “DBV”), a clinical-stage biopharmaceutical company, today announced the resignation of Daniel Soland, as a member of its Board of Directors (the “Board”), effective immediately. “On behalf of the Board, DBV’s management team and shareholders, I thank Daniel for his commitment to the Company,” said Michel de Rosen, Chairman of the Board. “Since joi...

September 18, 2025 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies annonce la démission d’un membre de son Conseil d’adm...

DBV Technologies annonce la démission d’un membre de son Conseil d’administration Châtillon, France, le 18 septembre 2025 DBV Technologies annonce la démission d’un membre de son Conseil d’administration DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (la “Société” ou “DBV”), une société biopharmaceutique au stade clinique, a annoncé ce jour la démission de Daniel Soland de ses fonctions d’administrateur au sein du Conseil d’administration de la Société (le « Conseil »), avec effet immédiat. “Au nom du Conseil, de l’équipe de direction de DBV et de nos act...

September 18, 2025 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq

DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq Châtillon, France, September 5, 2025 DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company, today announced that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (“SEC”) relating to an at-the-market offering (the “ATM Program”). Pursuant to this new financing program, the Company may offer and sell, including with unsolicited ...

September 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch